QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
NYSE:AZN

AstraZeneca - AZN Stock Forecast, Price & News

$63.76
+0.61 (+0.97%)
(As of 02/3/2023 10:32 AM ET)
Add
Today's Range
$63.37
▼
$64.09
50-Day Range
N/A
52-Week Range
$52.65
▼
$72.12
Volume
1.24 million shs
Average Volume
6.07 million shs
Market Capitalization
$197.58 billion
P/E Ratio
N/A
Dividend Yield
1.38%
Price Target
N/A
AZN stock logo

About AstraZeneca (NYSE:AZN) Stock

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. It focuses on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. These pharmaceutical products are then manufactured, marketed and sold. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Stock News Headlines

January 30, 2023 | marketbeat.com
Cassava Sciences Stock Undervalued with Its $124 Price Target? (AZN)
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
February 2, 2023 | stocknews.com
3 Pharma Stocks to Buy in 2023 and Hold for Decades
February 3, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
February 2, 2023 | markets.businessinsider.com
AstraZeneca, Amgen's Tezspire Pre-filled Pen Receives FDA Approval In US For Asthma
January 30, 2023 | finance.yahoo.com
Is AstraZeneca PLC (AZN) a High Growth Stock?
January 30, 2023 | americanbankingnews.com
AstraZeneca (NYSE:AZN) Raised to Strong-Buy at StockNews.com
January 26, 2023 | reuters.com
U.S. FDA withdraws authorization for AstraZeneca's Evusheld
January 26, 2023 | msn.com
AstraZeneca COVID-19 therapy no longer authorized in U.S.
February 3, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 26, 2023 | reuters.com
U.S. FDA pulls authorization for AstraZeneca's COVID-19 treatment Evusheld
January 26, 2023 | bizjournals.com
CinCor CEO: acquisition by AstraZeneca was more than a year in the making
January 25, 2023 | marketwatch.com
AstraZeneca rises Wednesday, outperforms market
January 25, 2023 | stocknews.com
2 Pharma Stocks to Buy Now for Big Gains in 2023
January 24, 2023 | marketwatch.com
AstraZeneca PLC ADR underperforms Tuesday when compared to competitors
January 24, 2023 | marketwatch.com
AstraZeneca falls Tuesday, underperforms market
January 23, 2023 | msn.com
CytoSorbents says Canada cleared pivotal study for anti-bleeding technology
December 9, 2022 | markets.businessinsider.com
AstraZeneca: Datopotamab Deruxtecan Shows Encouraging Objective Response Rate In Phase I Trial
December 8, 2022 | seekingalpha.com
Novartis iptacopan comes out successful in 2nd phase 3 trial rare blood disorder
December 8, 2022 | markets.businessinsider.com
AZN:Phase III Trial Of Capivasertib Combination Shows Improvement In PFS In Metastatic Breast Cancer
December 8, 2022 | markets.businessinsider.com
AZN:Camizestrant Delayed Disease Progression In Advanced ER-Positive Breast Cancer In Phase II Trial
December 5, 2022 | stocknews.com
5 Amazing Stocks You Won’t Ever Regret Buying
December 1, 2022 | reuters.com
AstraZeneca boosts cancer portfolio with $320 mln Neogene deal
November 30, 2022 | reuters.com
AstraZeneca to sell Ohio site to biotech firm Resilience
November 30, 2022 | proactiveinvestors.com
AstraZeneca sells Ohio manufacturing plant to National Resilience
November 29, 2022 | bizjournals.com
RNA startup led by Pfizer vets closes $52M investment round
November 28, 2022 | bizjournals.com
AstraZeneca acquires rights to potential COPD treatment in deal valued at up to $402M
November 21, 2022 | finance.yahoo.com
Here’s Why AstraZeneca PLC (AZN) Declined in the Third Quarter
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals: Major
Sub-Industry
N/A
Sector
Health Technology
Current Symbol
NYSE:AZN
CUSIP
N/A
CIK
901832
Web
N/A
Phone
442037495000
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
3,098,840,000
Free Float
N/A
Market Cap
$197.58 billion
Optionable
Optionable
Beta
N/A

Key Executives

  • Pascal Soriot
    Chief Executive Officer & Executive Director
  • Pam P. Cheng
    Executive VP-Operations & Information Technology
  • Aradhana Sarin
    Chief Financial Officer & Executive Director
  • Menelas NICOLAS Pangalos
    EVP-Biopharmaceuticals Research & Development
  • Cindy L. Hoots
    Chief Digital & Information Officer













AZN Stock - Frequently Asked Questions

How have AZN shares performed in 2023?

AstraZeneca's stock was trading at $69.15 at the beginning of 2023. Since then, AZN stock has decreased by 8.7% and is now trading at $63.15.
View the best growth stocks for 2023 here.

Is AstraZeneca a good dividend stock?

AstraZeneca (NYSE:AZN) pays an annual dividend of $0.91 per share and currently has a dividend yield of 1.38%.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Moderna (MRNA), Tesla (TSLA), AbbVie (ABBV), AT&T (T), Advanced Micro Devices (AMD) and Walmart (WMT).

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How do I buy shares of AstraZeneca?

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $63.15.

How much money does AstraZeneca make?

AstraZeneca (NYSE:AZN) has a market capitalization of $195.69 billion.

How can I contact AstraZeneca?

The company can be reached via phone at 442037495000.

This page (NYSE:AZN) was last updated on 2/3/2023 by MarketBeat.com Staff